The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B

被引:82
作者
Yuan, HJ
Yuen, MF
Wong, DKH
Sablon, E
Lai, CL
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China
[2] Fudan Univ, Dept Med, Zhongshan Hosp, Shanghai 200433, Peoples R China
[3] Innogenet NV, Ghent, Belgium
关键词
complications; core promoter mutations; HBV-DNA; precore mutations;
D O I
10.1111/j.1365-2893.2005.00603.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We studied the hepatitis B virus (HBV)-DNA levels below which the development of cirrhosis-related complications became unlikely in chronic hepatitis B (CHB). Seventy-nine Chinese CHB patients with cirrhosis-related complications and 158 age-, sex- and HBeAg status-matched patients without complications were enrolled. The precore and core promoter mutations were detected by the Line Probe assay (LiPA). HBVDNA levels were determined by Digene assay and Cobas Amplicor Monitor test. Patients with complications had higher HBVDNA levels than those without complications (P = 0.02). HBeAg-positive patients with complications had similar alanine transferase (ALT) and HBVDNA levels and frequency of precore mutations, but higher frequency of core promoter mutations (P = 0.003), compared with those without complications. Anti-HBe-positive patients with complications had higher ALT and HBVDNA levels (P < 0.01) but similar frequency of precore and core promoter mutations, compared with those without complications. Anti-HBe patients (24.5%) with complications had HBVDNA levels < 10(4) copies/mL. The major factor for the development of cirrhotic complications was viral loads but cirrhotic complications continued to develop in patients with HBVDNA levels below 10(4) copies/mL.
引用
收藏
页码:373 / 379
页数:7
相关论文
共 33 条
  • [1] High prevalence of 1762T 1764A mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers
    Baptista, M
    Kramvis, A
    Kew, MC
    [J]. HEPATOLOGY, 1999, 29 (03) : 946 - 953
  • [2] A NEW HEPATITIS-B VIRUS-STRAIN IN PATIENTS WITH SEVERE ANTI-HBE POSITIVE CHRONIC HEPATITIS-B
    BRUNETTO, MR
    STEMLER, M
    BONINO, F
    SCHODEL, F
    OLIVERI, F
    RIZZETTO, M
    VERME, G
    WILL, H
    [J]. JOURNAL OF HEPATOLOGY, 1990, 10 (02) : 258 - 261
  • [3] CARMAN WF, 1989, LANCET, V2, P588
  • [4] THE SIGNIFICANCE OF SPONTANEOUS HEPATITIS-B E-ANTIGEN SEROCONVERSION IN CHILDHOOD - WITH SPECIAL EMPHASIS ON THE CLEARANCE OF HEPATITIS-B E-ANTIGEN BEFORE 3 YEARS OF AGE
    CHANG, MH
    HSU, HY
    HSU, HC
    NI, YH
    CHEN, JS
    CHEN, DS
    [J]. HEPATOLOGY, 1995, 22 (05) : 1387 - 1392
  • [5] Role of silent hepatitis B virus in chronic hepatitis B surface antigen(-) liver disease
    Chemin, I
    Jeantet, D
    Kay, A
    Trépo, C
    [J]. ANTIVIRAL RESEARCH, 2001, 52 (02) : 117 - 123
  • [6] SURVIVAL AND PROGNOSTIC INDICATORS IN HEPATITIS-B SURFACE ANTIGEN-POSITIVE CIRRHOSIS OF THE LIVER
    DEJONGH, FE
    JANSSEN, HLA
    DEMAN, RA
    HOP, WCJ
    SCHALM, SW
    VANBLANKENSTEIN, M
    [J]. GASTROENTEROLOGY, 1992, 103 (05) : 1630 - 1635
  • [7] Lamivudine as initial treatment for chronic hepatitis B in the United States
    Dienstag, JL
    Schiff, ER
    Wright, TL
    Perrillo, RP
    Hann, HWL
    Goodman, Z
    Crowther, L
    Condreay, LD
    Woessner, M
    Rubin, M
    Brown, NA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (17) : 1256 - 1263
  • [8] Fang ZL, 1998, J MED VIROL, V56, P18, DOI 10.1002/(SICI)1096-9071(199809)56:1<18::AID-JMV4>3.0.CO
  • [9] 2-Q
  • [10] Immunopathogenesis of hepatitis B e antigen negative chronic hepatitis B infection
    Hadziyannis, SJ
    Vassilopoulos, D
    [J]. ANTIVIRAL RESEARCH, 2001, 52 (02) : 91 - 98